Hyperalgesia - Pipeline Insight, 2024

This “Hyperalgesia - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hyperalgesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hyperalgesia Understanding

Hyperalgesia: Overview

An increased sensitivity to feeling pain and an extreme response to pain. Hyperalgesia may occur when there is damage to the nerves or chemical changes to the nerve pathways involved in sensing pain. Both peripheral and central mechanisms play a role in the processing of primary afferent input that makes the transition from the normal signaling of unpleasant sensory experience to a hyperalgesic state. Hyperalgesia to heat is prevalent after a cutaneous injury and after inflammation. Hyperalgesia to heat can also develop after inflammation. When a cocktail of inflammatory mediators is injected into the receptive field of nociceptive afferents, marked sensitization to heat stimuli is observed. Hyperalgesia may occur after long exposure to opioids as opioid tolerance develops. The underlying mechanisms may involve activity of the pain modulatory circuitry.

Hyperalgesia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperalgesia pipeline landscape is provided which includes the disease overview and Hyperalgesia treatment guidelines. The assessment part of the report embraces, in depth Hyperalgesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Hyperalgesia R&D. The therapies under development are focused on novel approaches to treat/improve in Hyperalgesia.
• In May 2019, Lundbeck acquired Abide Therapeutics for $250m, Gains San Diego Discovery Site. Through the acquisition, Lundbeck will add Abide’s discovery platform focused on discovering potent and selective serine hydrolase inhibitors. While they represent just 1% of all mammal proteins, Lundbeck noted, they play key roles in many pathophysiological processes, including blood clotting, digestion, nervous system signaling, inflammation, and cancer.

This segment of the Hyperalgesia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperalgesia Emerging Drugs

ABX-1431: Abide TherapeuticsABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor. Abide’s lead candidate, ABX-1431 is a potent selective inhibitor of the serine hydrolase monoacylglycerol lipase (MGLL) that augments endocannabinoid signaling, with the goal of restoring homeostatic balance in the central nervous system.

IPNP2015: Initiator PharmaIPNP2015 is a proprietary triple reuptake inhibitor of 5-HT, NA, and DA. Initiator has tested IPNP2015 in rodent models of persistent and neuropathic pain. IPNP2015 possesses superior antinociceptive efficacy compared with the dual monoamine reuptake inhibitor duloxetine, and it is an attractive new drug candidate for the treatment of chronic pain. In preclinical studies, IPNP2015 has shown positive effect superior to the drug duloxetine.

Hyperalgesia: Therapeutic Assessment

This segment of the report provides insights about the different Hyperalgesia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hyperalgesia

There are approx. 5+ key companies which are developing the therapies for Hyperalgesia. The companies which have their Hyperalgesia drug candidates in the most advanced stage, i.e. Phase III include, Cara Therapeutics

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hyperalgesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Oligonucleotide

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperalgesia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperalgesia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperalgesia drugs.

Hyperalgesia Report Insights

• Hyperalgesia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hyperalgesia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hyperalgesia drugs?
• How many Hyperalgesia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperalgesia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hyperalgesia?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hyperalgesia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• OKYO Pharma
• Cara Therapeutics
• Abide Therapeutics
• Initiator Pharma

Key Products

• OK 201
• Difelikefalin
• Lu AG06466
• IPNP-2015

This product will be delivered within 1-3 business days.